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Abstract
Several reports have shown that circulating insulin level is positively correlated with arterial calcification; however, the
relationship between insulin and arterial calcification remains controversial and the mechanism involved is still unclear. We
used calcifying vascular smooth muscle cells (CVSMCs), a specific subpopulation of vascular smooth muscle cells that could
spontaneously express osteoblastic phenotype genes and form calcification nodules, to investigate the effect of insulin on
osteoblastic differentiation of CVSMCs and the cell signals involved. Our experiments demonstrated that insulin could
promote alkaline phosphatase (ALP) activity, osteocalcin expression and the formation of mineralized nodules in CVSMCs.
Suppression of receptor activator of nuclear factor kB ligand (RANKL) with small interfering RNA (siRNA) abolished the
insulin-induced ALP activity. Insulin induced the activation of extracellular signal-regulated kinase (ERK)1/2, mitogen-
activated protein kinase (MAPK) and RAC-alpha serine/threonine-protein kinase (Akt). Furthermore, pretreatment of human
osteoblasts with the ERK1/2 inhibitor PD98059, but not the phosphoinositide 3-kinase (PI3K) inhibitor, LY294002, or the Akt
inhibitor, 1L-6-hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate (HIMO), abolished the insulin-induced
RANKL secretion and blocked the promoting effect of insulin on ALP activities of CVSMCs. Recombinant RANKL protein
recovered the ALP activities decreased by RANKL siRNA in insulin-stimulated CVSMCs. These data demonstrated that insulin
could promote osteoblastic differentiation of CVSMCs by increased RANKL expression through ERK1/2 activation, but not
PI3K/Akt activation.
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Introduction
Arterial calcification is a significant predictor for cardiovascular
events in patient with diabetes mellitus and end-stage renal
disease. In these cases, the main cell type involved is the vascular
smooth muscle cell (VSMCs) [1,2]; however, the mechanisms for
arterial calcification still remain unclear.
There is an increasing amount of evidence to suggest that
medial arterial calcification is an active and tightly regulated
process that resembles mineralization in bone [1,2]. Key
functional aspects of bone formation and remodeling are
recapitulated in vascular calcification, and many bone-related
factors such as osteoprotegerin (OPG), receptor activator of NF-kB
ligand (RANKL), alkaline phosphatase (ALP), osteocalcin (OC)
and runt-related transcription factor 2 (RUNX2) have been found
in calcified areas of the arterial wall and VSMCs [3–5]. The
discovery that OPG-deficient mice develop severe osteoporosis
and arterial calcification [6,7] and that RANKL directly increased
VSMC calcification [8] provided the first clue that the RANKL/
OPG/RANK axis could be an important autocrine/paracrine axis
for vascular calcification.
Hyperinsulinemia is a clinic characteristic of type 2 diabetes as
a result of insulin resistance. Several studies have demonstrated
that insulin level and insulin resistance are positively correlated
with arterial calcification [9–14]. Moreover, an animal study of
Zucker diabetic rats, a hyperinsulinism model, increased arterial
stiffness that was related to arterial calcification [15,16].
However, the relationship between insulin and VSMCs calcifi-
cation remains controversial [17,18]. In the present study, we
used calcifying vascular smooth muscle cells (CVSMCs), referred
to as a specific subpopulation of VSMCs that could express
osteoblastic phenotype gene and form calcification nodule
spontaneously [19,20], to elucidate the effect of insulin on
osteoblastic differentiation of CVSMCs and the mechanisms
involved.
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Effects of insulin on the expression of RANKL mRNA and
protein in CVSMCs
Physiologically, insulin concentrations in vivo may rise to ,1n M
[21]. In the presence of insulin resistance, serum insulin
concentrations may exceed these levels. We performed insulin
dose–response and time course experiments to determine the effect
of physiological and supraphysiological concentrations of insulin
on mRNA levels and on RANKL protein secretion in CVSMCs.
After 48 h, insulin at a 1 nM concentration had no effect on the
expression of RANKL mRNA. RANKL mRNA levels increased
significantly at 5 nM insulin stimulation, and the maximal effect of
insulin was reached at 10 nM on RANKL mRNA levels. At
markedly supraphysiological insulin concentrations there was a
small decrease in RANKL mRNA levels compared with the
maximum effect of insulin (Fig. 1A). RANKL protein secretion
followed the mRNA trend (Fig. 1B). After 48 h of culture and at a
concentration of 10 nM of insulin, expression of RANKL mRNA
was greater than that of the controls (p,0.01) (Fig. 1C).
Insulin activated ERK1/2 and Akt signaling pathway in
CVSMCs
Recent studies have that demonstrated that ERK1/2 and Akt
signaling pathways mediate insulin action [22,23]. We examined if
insulin induced ERK1/2 and Akt signaling in CVSMCs. As
shown in Figure 2A, insulin stimulated the activity of a specific
ERK1/2 in the CVSMCs after 5 min of incubation, when
determined by the increase in the phosphorylated ERK1/2 levels
the peak activation of ERK1/2 occurred at 15–30 min. Then, we
examined whether insulin induced Akt signaling in CVSMCs.
Insulin treatment increased phosphorylated Akt (p-Akt) levels after
5 min of incubation; the peak activation of Akt occurred at
15 min.
The activation of ERK1/2 and Akt by insulin was abolished by
PD98059 (an inhibitor of ERK1/2), LY294002 (an inhibitor of
PI3-K) or HIMO (an inhibitor of Akt), respectively (Fig. 2B and
2C). These data indicated that insulin stimulated ERK and PI3-
K/Akt activation in CVSMCs.
ERK1/2 signaling pathway mediated insulin-regulated
RANKL expression in CVSMCs
Figure 2D showed that pretreatment of cells with the ERK1/2
inhibitor PD98059, but not the PI3K inhibitor LY294002 or the
Akt inhibitor HIMO blocked the increasing RANKL mRNA
expression stimulated by 10 nM insulin. To exclude any
nonspecific effect of PD98059, LY294002 or HIMO, we used
1a,25-dihydroxyvitamin D3 (1,25 vitD) and 1,25 vitD+PD98059
as the control (both at 10
27 M) to induce RANKL mRNA
expression. PD98059 did not block the increase in RANKL
mRNA expression induced by 1,25 vitD.
Insulin increased osteoblastic differentiation of CVSMCs
and calcification of CVSMCs
Mineralization of matrix. The calcification induced by
insulin was also visualized by Alizarin Red S staining, as we show
in Figure 3A. In this figure we show that incubation of CVSMCs
with insulin increased the red staining that marks calcified areas.
Figure 3B showed that insulin increased CVSMCs calcification as
measured by CVSMC calcium levels.
ALP activity, osteocalcin secretion assay. Figure 3C
showed the dose–response of effects of insulin on ALP activity in
cultured CVSMCs. At insulin concentrations of 5, 10, and
100 nM, ALP activity increased markedly. Figure 3D shows the
effects of insulin on osteocalcin secretion in cultured CVSMCs.
Treatment with 5–100 nM insulin caused a significant increase in
osteocalcin production and the maximal effect of insulin was
reached after addition of 10 nM insulin.
Involvement of RANKL and ERK1/2 signaling in insulin
regulation of osteoblastic differentiation of CVSMCs
In order to illuminate whether and how RANKL, ERK1/2,
and PI3K/Akt signaling was involved in the regulation of
osteoblastic differentiation of CVSMCs, we used siRNA to block
RANKL, and signal inhibitor to block ERK1/2, and PI3K/Akt
signal pathways, respectively. Then, we observed ALP activity,
which is an important phenotypic marker of osteoblastic
differentiation.
Figure 4A showed that pretreatment of cells with the ERK1/2
inhibitor PD98059, but not the PI3K inhibitor LY294002 or Akt
inhibitor HIMO blocked the increased ALP activity induced by
10 nM insulin. RANKL was knocked down efficiently by RNA
interference in CVSMCs (Fig. 4A). Suppression of RANKL with
siRNA-RANKL, but not control siRNA, also abolished the
increased ALP activity indued by 10 nM insulin (Fig. 4B).
Furthermore, 15 pM recombinant RANKL protein could recover
ALP activities in the insulin-induced RANKL-knocked down
CVSMCs (Fig. 4C). These data indicated that insulin-induced
osteoblastic differentiation of CVSMCs is mediated by the ERK1/
2/RANKL pathway.
Discussion
VSMCs can express RANKL and recent results have shown
that RANKL plays an important role in mediating arterial
calcification [8,24]. Our present data showed that insulin induced
RANKL expression in CVSMCs through the ERK1/2 signal
pathway, and these responses contributed to insulin-induced
CVSMCs calcification. These findings suggested that RANKL
induced by insulin in CVSMCs accelerated arterial calcification
through an antocrine or a paracrine effect.
Extensive epidemiological data have shown that diabetes is
correlated with arterial calcification and higher insulin level could
predicate arterial calcification independently [11,25]. The mech-
anisms of insulin involved in arterial calcification in these clinical
settings are still controversial. Olesen et al.’s result demonstrated
that insulin enhanced in vitro-induced calcification in VSMCs [17].
However, Wang et al. suggested that insulin attenuated VSMCs
calcification in high phosphate medium [18]. These contradictory
results might be explained by different cell types or different
experimental condition. Increasing ALP activities, osteocalcin
secretion is a marker of osteoblastic differentiation, and matrix
mineralization is a hallmark of osteoblast phenotype. In our
present study, we demonstrated that insulin upregulated ALP
activities, increased osteocalcin secretion and promoted mineral-
ization nodule formation. These results show that insulin
stimulated osteoblastic differentiation of CVSMCs and increased
CVSMC calcification, findings that are consistent with Olesen
et al.’s results [17].
RANKL is a member of the tumor necrosis factor superfamily
and is expressed mainly on osteoblasts and its immature
precursors. RANKL binds to RANK and is expressed on the cell
surface of hematopoietic osteoclast precursor cells, inducing
osteoclastogenesis and activation and prolonging osteoclast
survival by suppressing apoptosis. OPG acts as a decoy receptor
by binding to RANKL and blocking its interaction with RANK,
thus inhibiting osteoclast development. It has been suggested that
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of arterial calcification. The first evidence for an involvement of
OPG in arterial calcification was derived from OPG knockout
mice that displayed severe osteoporosis and arterial medial
calcification of the aorta and renal arteries. Furthermore,
administration of OPG can inhibit vascular calcification in
experimental animals [26,27]. Olesen et al. showed that insulin
could accelerate VSMC calcification and was accompanied by an
increase in OPG expression [17]. However, their results did not
explain if the altered OPG levels during the calcification could
directly regulate the calcification process or if it was just a
consequence of mineralization. Several studies have suggested that
RANKL is involved in VSMC calcification. In addition, RANKL
and RANKL transcripts could be detected in calcified arterial
lesions from experimental animals [7], and RANKL expression
was colocalized and upregulated in areas that displayed arterial
calcification [28,29]. In contrast, RANKL increased VSMC
calcification by binding to RANK and increased BMP4 produc-
tion through activation of the alternative NF-kB pathway [8]. Our
recent results demonstrated that RANKL plays a pivotal role in
Figure 1. Effect of in vitro incubation of calcifying vascular smooth muscle cells (CVSMCs) with insulin on RANKL expression. Cells
were exposed to vehicle or 1–100 nM insulin for 48 h or to 10 nM insulin for 6–48 h. (A) The dose–response of insulin on RANKL mRNA levels
measured by real-time polymerase chain reaction (PCR) in cultured CVSMCs. Data are shown as percentage over basal values. (B) The dose–response
of insulin on RANKL protein secreted by CVSMCs in the culture medium. (C) Time course of effects of 10 nM insulin on RANKL mRNA levels in cultured
CVSMCs. (D) Time course of effects of 10 nM insulin on RANKL protein secretion in the culture medium by CVSMCs. The dots represent the percent of
control RANKL levels at various time points. (n=3,*p,0.05 vs. control, **p,0.01 vs. control.).
doi:10.1371/journal.pone.0029037.g001
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cient mice [24]. Our present data showed that insulin could
increase the expression of RANKL and promote ALP activities in
CVSMCs, concurrently. Furthermore, inhibition of RANKL
expression by addition of siRNA abrogated the induction by
insulin of CVSMC ALP activity. Then, recombinant RANKL
protein recovered the ALP activity that was reduced by RANKL-
siRNA addition in insulin-stimulated CVSMCs. These data
suggest RANKL is the key regulator in insulin induced osteoclastic
differentiation of VSMCs. In contrast, Tseng et al.’s result showed
that upregulated RANKL induced by PKA in aortic smooth
muscle cells could not mediate matrix calcification [30]. We think
that these differences may result from use of a different cell model,
as our previous study confirmed adenovirus-mediated over-
expression of omentin-1 attenuated arterial calcification by
decreased in RANKL expression in OPG knockout mice [24].
Thus we have shown that insulin regulated osteoblastic differen-
tiation of CVSMCs through upregulation of RANKL in
CVSMCs.
To gain further insight into the mechanisms by which insulin
promoted RANKL expression in CVSMCs, we evaluated the
signaling events. Recent studies have demonstrated the existence
of two major signaling pathways, namely Akt and ERK1/2, which
mediate insulin action [22,23]. Signal transduction along both
pathways is initiated by insulin binding to the insulin receptor.
Transduction of insulin signal via the insulin receptor substrate
(IRS) proteins PI3K and Akt is responsible for most, if not all, of
the metabolic aspects of insulin action. The second signaling
pathway, which involves Ras, Raf, and ERK1/2, is responsible for
the mitogenic aspects of insulin action and is not involved in the
mechanisms of metabolic insulin action [31,32]. There are several
independent signaling pathways documented that regulate
RANKL expression in osteoblasts/stromal cells. These pathways
include the ERK1/2 pathway (annexin II), the vitamin D receptor
pathway [1,25 vitD], the protein kinase A pathway (parathyroid
hormone (PTH) and prostaglandin (PGE)2), the gp130 pathway
(interleukin (IL)-6 and IL-11), and the calcium/protein kinase C
pathway (high extracellular Ca
2+) [33–37]. Here, we reported that
insulin induced activation of Akt and ERK1/2 in CVSMCs.
Furthermore, we demonstrated that pretreatment of cells with
ERK1/2 inhibitor, but not PI3K inhibitor or Akt inhibitor,
abolished the insulin-promoted RANKL expression in CVSMCs.
These data indicated that insulin-induced RANKL expression was
mediated by the ERK1/2 pathway.
In conclusion, the present data has provided evidence that
insulin promoted osteoblastic differentiation of CVSMCs, and this
effect is mediated by the ERK1/2/RANKL pathway. These
findings suggest that insulin directly facilitates arterial calcification.
Materials and Methods
Reagents
Anti-rat extracellular signal-regulated kinase1/2 (ERK1/2), p-
ERK, Akt, p-Akt antibody, anti a-actin polyclonal antibody, anti-
RANKL, and rabbit IgG peroxidase conjugate antibodies were
purchased from Santa Cruz Biotechnology (Waltham, MA, USA).
The ERK 1/2 inhibitor PD98059, PI3K inhibitor LY294002 and
Figure 2. Insulin increased RANKL mRNA expression through
ERK1/2, but not Akt signal pathway in calcifying vascular
smooth muscle cells (CVSMCs). Cell lysates were subjected to
western blot and incubated with anti-p-ERK1/2, ERK1/2, p-Akt, and Akt
antibodies. (A) Effects of insulin on ERK1/2 and Akt activation in
CVSMCs. Representative results are shown for cells exposed to 10 nM
insulin for 5–60 min. (B) Cells incubated with PD98059 (10 mM) for 2 h
prior to treatment with 10 nM insulin for 30 min. (C) Cells incubated
with LY294002 (10 mM) or HIMO (10 mM) for 2 h prior to treatment with
10 nM insulin for 15 min. (D) Cells were incubated with PD98059
(10 mM), LY294002 (10 mM) or HIMO (10 mM) for 2 h before treatment
with 10 nM insulin for 48 h. Cells were treated with 10
27 M1 a,25-
dihydroxyvitamin D3 (1,25 vitD), or 1,25 vitD+10 mM PD98059 as
another control. RANKL mRNA expression was determined by real-time
quantitative PCR. Results are expressed as percent of control. Bars
represent mean 6 standard deviation (SD) (n=3;**p,0.01 vs. insulin-
treated control).
doi:10.1371/journal.pone.0029037.g002
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yl-3-O-octadecylcarbonate (HIMO) was purchased from Calbio-
chem (San Diego, CA, USA). Recombinant rat RANKL was
purchased from ABCAM (Cambridge, MA, USA).
Cell culture
Six-week-old male Sprague Dawley rats were sacrificed, the
aorta removed, and calcifying vascular smooth muscle cells
(CVSMCs) were isolated as described previously [20,38]. Briefly,
the aortas were removed under sterile conditions. The aortas were
rinsed several times in Hanks balanced salt solution, then the
adventitia was removed and the aortas were minced and digested
in 5 ml of digestion solution (0.125 mg/ml elastase, 0.25 mg/ml
soybean trypsin inhibitor, 10 mg/ml collagenase I, 2.0 mg/ml
crystallized bovine albumin, and 15 mM HEPES) at 37uC for
45 min. The cellular digests were filtered through sterile100-mM
nylon mesh, centrifuged at 1000 rpm for 10 min, and washed
twice in Dulbecco’s modified Eagle’s medium (DMEM) that
contained 10% fetal bovine serum (FBS; Gibco-BRL Corp., NY,
USA) before culture in the same medium. CVSMCs were isolated
from cultures in which multicellular nodules appeared spontane-
ously. Cells were cloned by limiting dilution and single cell
harvesting from these nodule-forming cultures. Cloned lines were
identified as CVSMCs by their positive staining with monoclonal
Figure 3. Insulin promoted the mineralization of the matrix in calcifying vascular smooth muscle cells (CVSMCs). CVSMCs were
cultured in DMEM that contained 10% fetal bovine serum (FBS) in 24-well plates, in the presence of vehicle or 10 nM insulin for 20 days.
Mineralization of the matrix was determined by Alizarin red S staining. (A) Representative microscopic view at a magnification of 6100. Left panel
showed CVSMCs incubated with vehicle, and the right panel showed CVSMCs incubated with 10 nM insulin for 12 days. (B) Quantification of Alizarin
red S stain through extraction with cetyl-pyridinium chloride. The amount of released dye was quantified by spectrophotometry at 540 nm. The bars
represent mean 6 standard deviation (SD) (n=4;**p,0.01 vs. control). (C) Cells were treated with vehicle (serum-free medium) or insulin at 1, 5, 10,
or 100 nM for 48 h in serum-free DMEM. ALP activity were determined and normalized to cell total protein. The dose–response of insulin on ALP
activity in cultured CVSMCs. (D) Cells were treated with vehicle (serum-free medium) or insulin at 1, 5, 10, or 100 nM for 48 h in serum-free DMEM.
Osteocalcin secretion were determined and normalized to cell total protein. The dose–response of insulin on osteocalcin secretion in cultured
CVSMCs. The bars represent mean 6 standard deviation (SD) (**p,0.01 vs. control, *p,0.05 vs. control, n=4).
doi:10.1371/journal.pone.0029037.g003
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and to form calcified nodules. This investigation conforms to the
Guide for the Care and Use of Laboratory Animals published by
the US National Institutes of Health (NIH Publication No. 85-23,
revised 1996). The approval was granted by the Second Xiangya
Hospital of Central South University Ethics Review Board, China
(No. 2010-S163).
ALP activity, osteocalcin secretion assay in cultured
CVSMCs
The cells were washed with PBS, and then the cells layers were
scraped into solution. The lysates were homogenized. Then, ALP
activity was assayed by spectrophotometric measurement of p-
nitrophenol release at 37uC. ALP activity was normalized to total
protein content of the cell layer. Osteocalcin released into the
culture media was measured using a specific radioimmunoassay kit
(DiaSorin Corp., Stillwater, MN, USA). To normalize protein
expression to total cellular protein, a fraction of the lysate solution
was used in a Bradford protein assay.
Real-time quantitative PCR assay for RANKL mRNA
expression
CVSMCs were plated in 25-cm
2 flasks in DMEM containing
10% FBS. After 4 days of culture, cells were subsequently treated
with vehicle (serum-free DMEM) or insulin at 1, 5, 10, or 100 nM
for 48 h in serum-free DMEM. Cultures were also exposed to fresh
serum-free medium with or without 10 nM insulin for 6–48 h.
SYBR green real time PCR assay was performed by Light-
Cycler technology (Roche) in 20 ml PCR mixture volume
consisting of 10 mlo f2 6 Quantitect SYBR Green PCR Master
Mix (Qiagen), containing HotStarTaq DNA polymerase,
500 nMof each oligonucleotide primer and 5 ml of retrotran-
scribed cDNA. Preliminary experiments were carried out for
primer concentration optimization. Primer sequences for RANKL
were 59-CATCGGGTTCCCATAAAG -39 and 59- GAAG-
CAAATGTTGGCGTA -39. For GAPDH, the PCR primers
were 59-ATCACTGCCACTCAGAAGAC-39 and 59-ACAT-
TGGGGGTAGGAACAC-39. Amplifications were performed,
and calibration curves were run in parallel in triplicates for each
analysis. Each sample was analyzed six times during each
experiment. The experiments were carried out at least twice.
Amplification data were analyzed using the Sequence Detector
System Software (PE Applied Biosystems). Relative quantification
were calculated by normalizing the test crossing thresholds (Ct)
with the GAPDH amplified control Ct. The results were
normalized to GAPDH and expressed as percentage of controls.
Soluble RANKL protein secretion assay
Levels of RANKL were determined in culture media superna-
tants of control cells and cells treated with insulin with
commercially available ELISAs (Biomedica, Vienna, Austria).
Detection of ERK 1/2 and Akt activation in CVSMCs
For studying the effects of insulin on the ERK 1/2 and Akt
signaling pathway, Western blot was performed using anti-p-ERK
Figure 4. Insulin-promoted osteoblastic differentiation of
calcifying vascular smooth muscle cells (CVSMCs) through
the ERK1/2/RANKL signaling pathway. (A) Treatment with siRNA-
RANKL blocked the expression of RANKL protein in osteoblasts. Cells
were treated with siRNA control, or siRNA-RANKL. Total cellular protein
was subjected to immunoblot analysis using anti-RANKL antibody. Lane
1, lysate from CVSMCs; lane 2, lysate from CVSMCs treated with siRNA
control; lane 3, lysate from CVSMCs treated with siRNA-RANKL. (B) The
cells were homogenized for ALP activity assay. Cells were incubated
with PD98059 (10 mM), HIMO (10 mM) or LY294002 (10 mM) for 2 h
before being treated with 10 nM insulin for 48 h. Cells were also treated
with siRNA control or siRNA-RANKL in the presence of 10 nM insulin.
(C) Effect of recombinant RANKL protein (15 pM) on the ALP activities
decreased by RANKL-siRNA in 10 nM insulin-stimulated CVSMCs after
48 h. (n=5;**p,0.01 vs. insulin-treated control).
doi:10.1371/journal.pone.0029037.g004
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The membrane was reprobed with secondary antibody for 1 h.
Blots were processed using an ECL kit (Amersham Biosciences)
and exposed to the film.
Measurement of mineralized matrix formation in
cultured CVSMCs
Measurment was determined as we previously described [38].
CVSMCs in 24-well plates were cultured in DMEM containing
10% FBS in the presence of 10 nM insulin or vehicle for 12 days.
The extent of mineralized matrix was determined by Alizarin Red
S staining. Briefly, cells were fixed in 70% ethanol for 1 h at room
temperature and stained with 40 mM Alizarin Red S for 10 min.
Next, cell preparations were washed with PBS to eliminate
nonspecific staining. The stained matrix was photographed using a
digital microscope. Alizarin Red S staining was released from cell
matrix by incubation in cetyl-pyridinium chloride for 15 min. The
amount of released dye was quantified by spectrophotometry at
540 nm. Results were then normalized to total cellular protein
values.
RNA interference for RANKL
RNA interference was used to down-regulate the expression of
RANKL in CVSMCs. Two small-interfering RNAs (siRNAs)
duplexes targeting rat RANKL gene were synthesized by Genesil
Biotechnology (Wuhan, China). The sequences of the sense rat
RANKL siRNAs used were 59-CGCGCUGCUUCUACA-
GAAUdTdT-39, these sequences of the antisense rant RANKL
siRNA used were 59-AUUCUGUAGAAGCAGCGCGdTdG-39
as previously described [40]. The scrambled control siRNA with
the same nucleotide composition as the RANKL siRNA but
lacking significant sequence homology to the rat genome was also
constructed. For gene knockdown experiments, CVSMCs plated
in a 60-mm diameter dish and cultured for 24 h in medium
without antibiotics. Cells were transfected with siRNAs (1 nmol/
well) using Lipofectamine 2000 (Invitrogen Inc., Carlsbad, CA,
USA) according to the manufacturer’s instructions. After 24 h of
culture, cells were retransfected with siRNAs or controls and then
recultured for another 48 h. Total RNA was extracted using
Trizol reagent (Gibco). Quantitative real-time PCR was per-
formed using Roche Molecular LightCycler (Roche Applied
Science, Indianapolis, IN, USA) as described previously.
Statistical analyses
Data are presented as the mean 6 SD. Comparisons were made
using a one-way ANOVA. All experiments were repeated at least
three times, and representative experiments are shown.
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